News

Novo dishes on its new Seattle R&D shop and seeks out new ideas in obesity

Novo Nordisk has made it official: The Danish drugmaker is making a full-fledged go at obesity R&D, looking to build a Seattle hub and hire up some investigators as it expands its research palate.

Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs.

Valeant talks up the billion-dollar potential of its Phase III eye drug

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that's the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.

Novartis' blockbuster hopeful scores a win in psoriatic arthritis

Jockeying with a slew of next-generation treatments, Novartis' new anti-inflammatory drug succeeded in two Phase III trials on patients with psoriatic arthritis, stoking the company's hopes of snagging significant market share once it wins approval.

Regado slashes staff to preserve cash following PhIII fiasco

Regado had all of its eggs in one basket when it took its lead therapy into a Phase III trial on its own. And now that the anticoagulant study has been shelved after signs of a severe allergic reaction were seen among patients, the biotech is cutting more than half of its staffers in an effort to preserve cash and review what kind of moves it can still make.

Adaptimmune gathers $104M to fuel hot immuno-oncology tech race

A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.

VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle

Back at the beginning of this month, Seattle-based VentiRx spread the news that it had raised a venture round for its newly fast-tracked TLR8 cancer vaccine research, but didn't disclose just how much it had in hand. A new filing at the SEC, though, puts the venture figure at $50.6 million, with another $2.4 million or so left to add in the planned raise.

Gilead heads to FDA after wrapping a PhIII HIV combo drug program

Gilead says that a pair of late-stage studies of its single-tablet combo therapy for HIV hit their primary endpoints, paving the way to an FDA filing later in the year.

Bristol-Myers blueprints a 2,500-worker campus in New Jersey

Bristol-Myers Squibb is gearing up to build a 2,500-employee campus in New Jersey, following the biopharma trend of ditching far-flung outposts in favor of collaboration-encouraging hubs.

Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA

Lipocine is touting positive late-stage results for its testosterone replacement pill, gearing up for intense FDA scrutiny amid a sea change in how the regulator looks at so-called low-T treatments.

Novartis-partnered Eureka rounds up $21M round for immuno-oncology drug research

Eight months after partnering with Novartis, Emeryville, CA-based Eureka Therapeutics has landed a $21 million round led by a Chinese private equity firm. Beijing-based Yuan Capital led the round, with Majuven and all the current major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital, joining in.

Waksal's back: Once-jailed biotech chief plots an IPO for his latest play

Five years after wrapping up his prison term over an insider trading scandal, biotech veteran Sam Waksal says he's ready to take another company public, plotting a debut for Kadmon.

UPDATED: Acorda snags Phase III Parkinson's drug in $525M cash buyout

Acorda Therapeutics is gambling $525 million on a Phase III-ready Parkinson's treatment, striking an all-cash deal to buy Civitas Therapeutics.

Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug

With a big corporate split looming ahead, Baxter has stepped in to pick up the ex-U.S. rights to Merrimack Pharmaceuticals' lead cancer therapy, paying $100 million in an upfront fee and committing up to $870 million in additional milestones for the late-stage treatment.

Boehringer Ingelheim slashing 600 staffers as sales slide

The bloodletting in Big Pharma continues with news today that Boehringer Ingelheim is planning between 500 and 600 job cuts in its home country of Germany.

Fast-tracked Ebola studies put Tekmira, Mapp and Sarepta in the spotlight

On Monday Tekmira noted that the FDA had cleared the regulatory path needed to allow the use of its experimental Ebola treatment on a compassionate use basis. And then today the Vancouver-based biotech followed up with the news that it is collaborating with health officials on a fast-tracked study of Ebola therapies in Africa, a one-two punch that helped bolster its stock price as investors gambled on a successful outcome forged out of a lethal outbreak.

Biogen shoulders into gene therapy amid a second honeymoon for the field

As researchers and investors toast renewed optimism for a new generation of gene therapies, biotech bellwether Biogen Idec is deepening its commitment to the space, another sign of life for the resurgent field.

NEA pitches in on a $27M gamble on Tracon's mid-stage cancer drug program

New Enterprise Associates has stepped up to back San Diego-based Tracon Pharmaceuticals, joining a syndicate that is betting $27 million on the company's two cancer therapies, including a mid-stage drug now in the clinic for soft tissue sarcoma.

Molecular Partners plots a $134M IPO for some R&D me-time

On the heels of some A-list biopharma partnerships, Switzerland's Molecular Partners is looking to double down on its in-house projects, swinging for a $134 million IPO to help pay its way.